⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5030916 | 0.89 | MEN1 (0.32) | — | |
| SCHEMBL5030915 | 0.83 | GPR139 (0.30) | — | |
| SCHEMBL14285908 | 0.81 | ALDH1A1 (0.34) | — | |
| SCHEMBL5035241 | 0.81 | MAPT (0.35) | — | |
| SCHEMBL3745941 | 0.80 | ATM (0.34) | — | |
| SCHEMBL5028711 | 0.79 | POLB (0.32) | — | |
| SCHEMBL14626448 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL5035229 | 0.76 | ALDH1A1 (0.38) | — | |
| SCHEMBL5031758 | 0.73 | P2RX3 (0.36) | — | |
| SCHEMBL14285902 | 0.72 | MEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| WO-2007010015-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |